Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441 | General Counsel | August 17, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MADRIGAL PHARMACEUTICALS, INC.
Report date August 17, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,474 |
Reported balance
After 2026-08-17 transaction · row 1
1 source rowRow 1 · 2026-08-17 · Sale · Disposed 664 · Balance 11,474 F1: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 20, 2026 20:20 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 664 | $514.97 | $341,940.08 |
DisclosureSEC source: 0001628280-26-058256 · wk-form4_1787257250.xml · nonDerivative · entry 1 Kelley Shannon T · CIK 0002034056 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,474 F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. Read SEC document |
| March 06, 2026 Filed Mar 6, 2026 23:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 360 | $431.94 | $155,498.40 |
DisclosureSEC source: 0001628280-26-015763 · wk-form4_1772840042.xml · nonDerivative · entry 2 Kelley Shannon T · CIK 0002034056 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,138 F2 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 5,022 | $0.00 Strike: $434.80 | $0.00 |
DisclosureSEC source: 0001628280-26-015763 · wk-form4_1772840042.xml · derivative · entry 3 Kelley Shannon T · CIK 0002034056 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,022 Underlying: Common Stock · 5,022 shares Expires 2036-03-04 F3 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:34 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 4,017 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-015763 · wk-form4_1772840042.xml · nonDerivative · entry 1 Kelley Shannon T · CIK 0002034056 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,498 F1 · kind: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| January 20, 2026 Filed Jan 20, 2026 22:58 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 429 | $501.40 | $215,100.60 |
DisclosureSEC source: 0001628280-26-002742 · wk-form4_1768949897.xml · nonDerivative · entry 2 Kelley Shannon T · CIK 0002034056 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,481 F2 · kind: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2024. Read SEC document |
| January 20, 2026 Filed Jan 20, 2026 22:58 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 263 | $490.77 | $129,072.51 |
DisclosureSEC source: 0001628280-26-002742 · wk-form4_1768949897.xml · nonDerivative · entry 1 Kelley Shannon T · CIK 0002034056 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,910 F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. Read SEC document |
| August 18, 2025 Filed Aug 18, 2025 21:33 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 42 | $376.62 | $15,818.04 |
DisclosureSEC source: 0002034056-25-000009 · wk-form4_1755552828.xml · nonDerivative · entry 8 Kelley Shannon T · CIK 0002034056 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,173 F2 · kind: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2024. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $376.60 to $376.64, inclusive. Read SEC document |
| August 18, 2025 Filed Aug 18, 2025 21:33 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 190 | $375.75 | $71,393.18 |
DisclosureSEC source: 0002034056-25-000009 · wk-form4_1755552828.xml · nonDerivative · entry 7 Kelley Shannon T · CIK 0002034056 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,215 F2 · kind: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2024. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $375.46 to $376.06, inclusive. Read SEC document |
| August 18, 2025 Filed Aug 18, 2025 21:33 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 68 | $374.13 | $25,441.14 |
DisclosureSEC source: 0002034056-25-000009 · wk-form4_1755552828.xml · nonDerivative · entry 6 Kelley Shannon T · CIK 0002034056 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,405 F2 · kind: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2024. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $373.77 to $374.36, inclusive. Read SEC document |
| August 18, 2025 Filed Aug 18, 2025 21:33 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 252 | $372.44 | $93,854.88 |
DisclosureSEC source: 0002034056-25-000009 · wk-form4_1755552828.xml · nonDerivative · entry 5 Kelley Shannon T · CIK 0002034056 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,473 F2 · kind: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $372.25 to $372.76, inclusive. Read SEC document |
| August 18, 2025 Filed Aug 18, 2025 21:33 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 84 | $371.35 | $31,193.40 |
DisclosureSEC source: 0002034056-25-000009 · wk-form4_1755552828.xml · nonDerivative · entry 4 Kelley Shannon T · CIK 0002034056 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,725 F2 · kind: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $371.22 to $371.48, inclusive. Read SEC document |
| August 18, 2025 Filed Aug 18, 2025 21:33 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 84 | $370.06 | $31,085.04 |
DisclosureSEC source: 0002034056-25-000009 · wk-form4_1755552828.xml · nonDerivative · entry 3 Kelley Shannon T · CIK 0002034056 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,809 F2 · kind: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2024. Read SEC document |
| August 18, 2025 Filed Aug 18, 2025 21:33 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 126 | $369.64 | $46,574.89 |
DisclosureSEC source: 0002034056-25-000009 · wk-form4_1755552828.xml · nonDerivative · entry 2 Kelley Shannon T · CIK 0002034056 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,893 F2 · kind: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $369.02 to $369.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 18, 2025 Filed Aug 18, 2025 21:33 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 458 | $358.66 | $164,266.28 |
DisclosureSEC source: 0002034056-25-000009 · wk-form4_1755552828.xml · nonDerivative · entry 1 Kelley Shannon T · CIK 0002034056 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,019 F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 5,368 | $0.00 Strike: $347.28 | $0.00 |
DisclosureSEC source: 0001628280-25-011354 · wk-form4_1741384239.xml · derivative · entry 2 Kelley Shannon T · CIK 0002034056 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,368 Underlying: Common Stock · 5,368 shares Expires 2035-03-05 F2 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 5, 2026) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 3,187 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-011354 · wk-form4_1741384239.xml · nonDerivative · entry 1 Kelley Shannon T · CIK 0002034056 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,477 F1 · kind: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 5, 2026, March 5, 2027, March 5, 2028 and March 5, 2029, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:36 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 415 | $335.00 | $139,025.00 |
DisclosureSEC source: 0001628280-25-010510 · wk-form4_1741210575.xml · nonDerivative · entry 1 Kelley Shannon T · CIK 0002034056 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,290 F1 · kind: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2024. Read SEC document |
| January 17, 2025 Filed Jan 18, 2025 00:10 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 277 | $273.41 | $75,734.57 |
DisclosureSEC source: 0001628280-25-001902 · wk-form4_1737159023.xml · nonDerivative · entry 1 Kelley Shannon T · CIK 0002034056 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,705 F1 · kind: The sale reported on this Form 4 represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. Read SEC document |
| August 15, 2024 Filed Aug 20, 2024 00:16 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 7,820 | $0.00 Strike: $244.50 | $0.00 |
DisclosureSEC source: 0000950170-24-098804 · ownership.xml · derivative · entry 2 Kelley Shannon T · CIK 0002034056 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,820 Underlying: Common Stock · 7,820 shares Expires 2034-08-15 F2 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (August 15, 2025) and, thereafter, 6.25% of the shares shall vest on each quarterly anniversary following the first anniversary, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| August 15, 2024 Filed Aug 20, 2024 00:16 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 5,215 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-098804 · ownership.xml · nonDerivative · entry 1 Kelley Shannon T · CIK 0002034056 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,982 F1 · shares: Represents restricted stock units, which vest as to 25% of the shares on each of August 15, 2025, August 15, 2026, August 15, 2027 and August 15, 2028, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.